Clinical Trial Update: A Study of Subcutaneous At Home Administration of Trastuzumab (Herceptin) in Participants With Human Epidermal Growth Factor Receptor 2-positive (HER2+) Early Breast Cancer (eBC) [Phase 3]

View source ↗

Summary

Phase 3 study evaluating subcutaneous at-home administration of trastuzumab (Herceptin) in HER2-positive early breast cancer; study completed with results poste…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• HERCEPTIN (trastuzumab)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Breast Cancer | Phase 3 | Status: COMPLETED | Results posted: 2019-09-18